Accelerate Diagnostics, Inc. is an in-vitro diagnostics company providing solutions to improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The Company is focused on reducing the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to approximately five hours, rather than the two to three days required to deliver identification and susceptibility results. It has developed a diagnostic platform, the Accelerate ID/AST System (the ID/AST System), intended for the rapid diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. Accelerate Diagnostics UK Limited is a subsidiary of the Company.